Hepatic transcriptomic signatures of statin treatment are associated with impaired glucose homeostasis in severely obese patients.
Daniel Margerie, Philippe Lefebvre, Violeta Raverdy...
https://pubmed.ncbi.nlm.nih.gov/31159817/Actively Recruiting
Led by University Hospital, Lille · Updated on 2025-12-08
20000
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are investigating the relationship between obesity and type 2 diabetes, conditions influenced by both genetic and environmental factors. This study aims to better understand how different genetic variations affect gene expression in tissues involved in glucose and lipid metabolism, which may contribute to what is called diabesity, a combined condition of diabetes and obesity. The study uses advanced genomic techniques and bioinformatics to analyze these factors in both humans and animal models. Participants in this observational study are grouped based on their body mass index BMI and diabetes or glucose intolerance status. Groups include individuals with BMI 35 kgm2 with diabetes, glucose intolerance, or without diabetes, as well as those with BMI < 27 kgm2 and BMI between 27 and 35 kgm2 without diabetes. Samples are collected during abdominal surgeries such as bariatric surgery or cholecystectomy to study gene expression and metabolic pathways. During the study, researchers collect biological samples at baseline and follow participants over several years to assess changes in gene expression and insulin resistance. They also evaluate clinical and biological features before and after bariatric surgery at 1, 2, and 5 years. The primary measurement focuses on gene expression in tissues related to glucose metabolism. This long-term observation helps to understand the genetic and phenotypic factors influencing obesity and diabetes, with participation lasting up to 5 years.
CONDITIONS
A Biological Atlas of Severe Obesity (Biological Tissue Collection)
F
Francois PATTOU, MD PhD
V
Violeta Raverdy, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University Hospital, Lille
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Day of surgery and immediate recovery period
Participants undergo abdominal surgery such as bariatric surgery, gallbladder removal, or abdominal wall surgery during which biological tissue samples are collected.
1 surgical visit (in-person)
Duration - Up to 5 years
Participants are followed prospectively to assess clinical and biological features related to obesity and diabetes, including gene expression and insulin resistance indices.
Follow-up visits at 1 year, 2 years, and 5 years (in-person)
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
5
Have more questions? Get in touch with our team for quick support
Daniel Margerie, Philippe Lefebvre, Violeta Raverdy...
https://pubmed.ncbi.nlm.nih.gov/31159817/Patrick Saux, Pierre Bauvin, Violeta Raverdy...
https://pubmed.ncbi.nlm.nih.gov/37652841/Fleur Lien, Alexandre Berthier, Emmanuel Bouchaert...
https://pubmed.ncbi.nlm.nih.gov/24531544/Violeta Raverdy, Estelle Chatelain, Guillaume Lasailly...
https://pubmed.ncbi.nlm.nih.gov/37987186/University Hospital, Lille
Lead Sponsor